What is Esophagogastric adenocarcinoma?

Gastroesophageal junction adenocarcinoma is a rare type of cancer of the esophagus, the tube that connects your mouth and stomach. It starts in the gastroesophageal (GE) junction, the area where the esophagus and stomach join together. The cancer grows from cells that make mucus.

Does anyone survive stage 4 esophageal cancer?

The overall prognosis in stage IV esophageal adenocarcinoma remains poor. The estimated 5-year mortality for stage IV disease exceeds 85% to 90% [5].

Can you survive cancer of the esophagus?

The 5-year survival rate of people with cancer located only in the esophagus is 47%. The 5-year survival rate for those with disease that has spread to surrounding tissues or organs and/or the regional lymph nodes is 25%. If it has spread to distant parts of the body, the survival rate is 5%.

Which is immunohistochemical panel for distinguishing esophageal adenocarcinoma?

Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping

What causes adenocarcinoma in the esophagus?

Esophageal adenocarcinomas are most commonly seen in patients with visible columnar-lined esophagus (CLE) that is caused by severe reflux associated with abdominal LES damage >25mm. Esophageal adenocarcinoma results from the chronic exposure of the squamous epithelium to gastric contents.

How are microarrays used to diagnose esophageal squamous cell carcinomas?

Tissue microarrays with 69 esophageal adenocarcinomas and 41 whole sections of esophageal squamous cell carcinomas were stained for these markers and semiquantitatively scored. Sensitivities and specificities were calculated for individual markers and select combinations using the morphological diagnosis as a gold standard.

What is the overall mortality rate for esophageal adenocarcinoma?

The overall mortality in esophageal adenocarcinoma is determined almost entirely by the ratio of early to advanced cases. At present, overall mortality is 85% to 90%, indicating that there is a failure of early detection of esophageal adenocarcinoma. Symptomatic GERD is a premalignant disease.